<DOC>
	<DOCNO>NCT00093444</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , liposomal doxorubicin , work different way stop tumor cell divide stop grow die . Radiofrequency ablation use high-frequency electric current kill tumor cell . Combining radiofrequency ablation liposomal doxorubicin may increase effectiveness drug kill tumor cell . PURPOSE : This phase I trial study best dose liposomal doxorubicin give radiofrequency ablation treat patient primary metastatic liver tumor .</brief_summary>
	<brief_title>Heat Activated Liposomal Doxorubicin Radiofrequency Ablation Treating Patients With Primary Metastatic Liver Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose heat activate doxorubicin HCl liposome combine radiofrequency ablation patient primary metastatic tumor liver . - Determine pharmacokinetics pharmacodynamics drug patient . OUTLINE : This dose-escalation study heat activate doxorubicin HCl liposome . Patients receive doxorubicin HCl liposome IV 30 minute . Approximately 15 minute begin doxorubicin HCl liposome infusion , patient undergo radiofrequency ablation needle insert tumor ( ) heat target temperature approximately 12-60 minute . Cohorts 3-6 patient receive escalate dos heat activate doxorubicin HCl liposome maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . At least 6 patient treated MTD . Patients follow 28 day , every 3 month 1 year , every 6 month 2 year . PROJECTED ACCRUAL : Approximately 30 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm tumor liver Primary metastatic disease No 4 lesion No single lesion &gt; 7 cm maximum diameter Not candidate curative surgical resection due tumor histology prior surgery PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy At least 3 month Hematopoietic Platelet count ≥ 75,000/mm^3 WBC ≥ 1,500/mm^3 Hemoglobin ≥ 10 g/dL ( transfusion attain level ≥ 10g/dL allow ) Hepatic Bilirubin ≤ 2.0 mg/dL PT PTT ≤ 1.5 time control ( except patient receive anticoagulation therapy unrelated medical condition [ e.g. , atrial fibrillation ] ) Renal Creatinine ≤ 2.5 mg/dL Cardiovascular See Hepatic Ejection fraction ≥ 50 % MUGA No congestive heart failure No myocardial infarction within past 6 month No cerebral vascular accident within past 6 month No lifethreatening cardiac arrhythmia Other Weight &lt; 136 kg Glucose ≤ 300 mg/dL No uncontrolled diabetes No know serious uncontrolled reaction ( e.g. , anaphylaxis ) contrast agent use study No known allergy egg egg product No serious medical illness Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent interferon No live vaccine ( immunosuppressed patient ) 30 day study treatment Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery See Disease Characteristics Other More 3 week since prior therapy liver tumor ( ) More 3 week since prior systemic therapy nonlifethreatening extrahepatic disease recover No concurrent systemic therapy No administration follow medication 30 day study treatment : Cyclosporine Phenobarbital Phenytoin Streptozocin No concurrent administration follow medication : Amphotericin B injection Antithyroid agent overactive thyroid Azathioprine Chloramphenicol Colchicine Flucytosine Ganciclovir Plicamycin Zidovudine Probenecid Sulfinpyrazone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
</DOC>